for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AxoGen Inc

AXGN.OQ

Latest Trade

13.99USD

Change

-0.16(-1.13%)

Volume

59,811

Today's Range

13.88

 - 

14.10

52 Week Range

11.91

 - 

39.27

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.15
Open
14.05
Volume
59,811
3M AVG Volume
11.36
Today's High
14.10
Today's Low
13.88
52 Week High
39.27
52 Week Low
11.91
Shares Out (MIL)
39.26
Market Cap (MIL)
555.46
Forward P/E
-30.99
Dividend (Yield %)
--

Next Event

AxoGen Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

James Flynn Reports 6.29% Passive Stake In Axogen Inc

Axogen Inc Reports Q2 2019 Results

Axogen Reports Q1 Loss Per Share $0.24

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AxoGen Inc

AxoGen, Inc. offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers the AxoTouch Two-Point Discriminator, and AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation; assessing return of sensory, grip and pinch function; evaluating treatment interventions, and providing feedback to patients on nerve function. Its portfolio of products is available in the United States, Canada, the United Kingdom and several European and other countries. The Company's products are used by surgeons during surgical interventions to repair a range of nerve injuries throughout the body.

Industry

Medical Equipment & Supplies

Contact Info

13631 Progress Blvd Ste 400

+1.386.4626817

https://www.axogeninc.com/

Executive Leadership

Karen L. Zaderej

Chairman of the Board, President, Chief Executive Officer

Peter J. Mariani

Chief Financial Officer

Maria D. Martinez

Chief Human Resource Officer

David Hansen

Vice President - Finance, Treasurer

Mike Donovan

Vice President - Operations

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.390

2017

-0.310

2018

-0.340

2019(E)

-0.457
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.78
Price To Book (MRQ)
4.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.04
LT Debt To Equity (MRQ)
0.03
Return on Investment (TTM)
-17.77
Return on Equity (TTM)
-16.31

Latest News

BRIEF-Axogen Inc Announces Closing Of Public Offering Of Common Stock

* AXOGEN, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-AxoGen Upsizes Public Offering To 3 Mln Shares At $41 Per Share

* AXOGEN, INC. ANNOUNCES UPSIZING AND PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-AxoGen Announces Proposed Public Offering Of Common Stock

* AXOGEN INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 2 MILLION SHARES OF ITS COMMON STOCK

BRIEF-AxoGen Reports Q1 Loss Per Share Of $0.16

* FY2018 REVENUE VIEW $84.9 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Axogen Inc Q4 Adjusted Loss Per Share $0.07

* AXOGEN, INC. REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-Axogen Sees Q4 Revenue At Least $16.5 Million

* FY2017 REVENUE VIEW $59.2 MILLION -- THOMSON REUTERS I/B/E/S

BRIEF-Axogen Announces Avance Nerve Graft Recipient Selected To Ride On Donate Life Rose Parade Float

* AXOGEN CORPORATION ANNOUNCES AVANCE® NERVE GRAFT RECIPIENT SELECTED TO RIDE ON DONATE LIFE ROSE PARADE® FLOAT Source text for Eikon: Further company coverage:

BRIEF-Axogen, Inc. Announces pricing of public offering of common stock

* Axogen, Inc. Announces pricing of public offering of common stock

BRIEF-Axogen announces proposed public offering of common stock

* Axogen Inc announces proposed public offering of common stock

BRIEF-AxoGen reports Q3 loss per share $0.06

* Fy2017 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S

BRIEF-AxoGen files for resale of up to 4.9 mln shares of co's common stock

* AxoGen Inc files for resale of up to 4.9 million shares of co's common stock by selling shareholder - SEC filing Source text: (http://bit.ly/2kfE1Zn) Further company coverage:

BRIEF-AxoGen Inc Q2 loss per share $0.06

* Sees fy 2017 revenue up at least 40 percent Source text for Eikon: Further company coverage:

BRIEF-Axogen sees 2017 revenue up at least 40 percent

* Sees fy 2017 revenue up at least 40 percent Source text for Eikon: Further company coverage:

BRIEF-Axogen sees FY 2017 revenue up at least 40 percent

* Axogen Inc - management increases its full year 2016 revenue guidance to at least $41.0 million from its previous estimate of over $40.0 million

BRIEF-Axogen Inc says qtrly loss per share $0.08

* Axogen, inc. Reports financial results for third quarter 2016

BRIEF-Axogen Inc announces refinancing of its debt facility

* Axogen Inc says new facility consists of a $21.0 million term loan and a $10.0 million revolving line of credit, of which $4.0 million has been drawn Source text for Eikon: Further company coverage:

BRIEF-Axogen announces proposed public offering of common stock

* Intends to use net proceeds of offering for expanded development of new nerve repair markets and products Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up